In particular, retrospective analyses have shown that combination treatment with TKIs and anti–PD-1 antibodies have reduced tumor burden sufficiently in a proportion of patients with advanced HCC, enabling them to undergo R0 resection [13–15]. This evidence concerns the gene RPL17 and hepatocellular carcinoma.